CVRx, Inc.
Case Overview
60 Days Left to Seek Lead Plaintiff
| Lead Plaintiff Deadline: | Lead Plaintiff Deadline:01/08/2027 |
| Status: | Status:Investigating |
| Company Name: | Company Name:CVRx, Inc. |
| Court: | Court:District of Minnesota |
| Case Number: | Case Number:0:26cv04746 |
| Class Period: | Class Period:07/25/2023 - 08/06/2026 |
| Ticker: | Ticker:CVRX |
| Related Attorneys: | Lead Attorneys:Thomas W. Elrod |
| Related Practices: | Related Practices:Securities |
The lawsuit alleges that CVRx made materially false and/or misleading statements and failed to disclose that: (i) to induce sales growth, CVRx and/or its employees were engaged in illegal and unsustainable sales practices, including improperly marketing Barostim, offering or paying kickbacks, and providing false information to government health insurance programs in violation of the False Claims Act (“FCA”) and Anti-Kickback Statute (“AKS”); (ii) CVRx’s revenues were in part the product of such unlawful conduct and thus unsustainable; and (iii) the illegal sales and marketing activities increased the risk of criminal and civil liability.
On August 6, 2026, CVRx filed with the SEC a Quarterly Report on Form 10-Q, disclosing that, on May 14, 2026, the Company “received a civil investigative demand (‘CID’) from the U.S Department of Justice in connection with an investigation under the False Claims Act.” CVRx stated, “The CID requested information and documents regarding an investigation into whether we caused the submission of false claims to government health insurance programs by improperly marketing our device, offering or paying kickbacks to healthcare providers or providing false information to government health insurance programs.” Additionally, the Company lowered its revenue guidance, citing challenges with sales force productivity. On this news, the price of CVRx shares declined by $3.55 per share, or approximately 60%, from $5.94 per share on August 6, 2026 to close at $2.39 on August 7, 2026.
On August 6, 2026, CVRx filed with the SEC a Quarterly Report on Form 10-Q, disclosing that, on May 14, 2026, the Company “received a civil investigative demand (‘CID’) from the U.S Department of Justice in connection with an investigation under the False Claims Act.” CVRx stated, “The CID requested information and documents regarding an investigation into whether we caused the submission of false claims to government health insurance programs by improperly marketing our device, offering or paying kickbacks to healthcare providers or providing false information to government health insurance programs.” Additionally, the Company lowered its revenue guidance, citing challenges with sales force productivity. On this news, the price of CVRx shares declined by $3.55 per share, or approximately 60%, from $5.94 per share on August 6, 2026 to close at $2.39 on August 7, 2026.